HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Sponsor

SYZ Cell Therapy Co.. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05952947

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.

Condition or Disease	Intervention/Treatment	Phase
Cervical Cancer Head and Neck Squamous Cell Carcinoma Carcinoma of Vagina Carcinoma of Penis Anal Cancer Carcinoma of Vulva	Biological: HRYZ-T101 Injection Drug: Fludarabine + Cyclophosphamide	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

32 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Single Arm, Open Label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Anticipated Study Start Date :

Oct 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2027

Anticipated Study Completion Date :

Feb 1, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: HRYZ-T101 Injection Patients will undergo lymphocytapheresis, then treatment with HRYZ-T101 TCR-T cells.	Biological: HRYZ-T101 Injection On day 1, the TCR-T cells will be administered intravenously. Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Arm

Intervention/Treatment

Experimental: HRYZ-T101 Injection

Patients will undergo lymphocytapheresis, then treatment with HRYZ-T101 TCR-T cells.

Biological: HRYZ-T101 Injection

On day 1, the TCR-T cells will be administered intravenously.

Drug: Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Outcome Measures

Primary Outcome Measures

DLT [28 days]
Dose-limiting toxicity
Adverse events and serious adverse events [2 years]
Incidence of adverse events and serious adverse events

Secondary Outcome Measures

Objective Response Rate（ORR） [2 years]
The percentage of subjects with PR or CR assessed by RECIST 1.1.
Disease Control Rate (DCR) [2 years]
The percentage of subjects with a confirmed CR, PR, or stable disease (SD) assessed by RECIST 1.1.
Duration of response (DoR) [2 years]
Subjects who show a confirmed CR or PR as assessed by RECIST 1.1.
Time to response (TTR) [2 years]
Time from date of T-cell administration to first documented evidence of confirmed (CR or PR) as assessed by RECIST 1.1.
Progression-Free Survival（PFS） [2 years]
The length of time from enrollment until the time of progression of disease.
Overall Survival (OS) [2 years]
The interval of time between the date of T-cell infusion and the date of death.
Duration of TCR T cells in-vivo persistence [2 years]
Blood samples were collected to measure persistence of infused HRYZ-T101.
Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ) [2 years]
Collect blood samples and analyze for presence of cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ) at specified intervals before and after treatment with HRYZ-T101.

Other Outcome Measures

Number of Subjects with positive anti-drug antibodies (ADA) [2 years]
Serum samples will be collected to analyze for the presence of ADAs using validated immunoassays.
Number of subjects with replication competent lentivirus (RCL) [2 years]
RCL exposure will be assessed by polymerase chain reaction (PCR) based assay.
T cell subgroup in peripheral blood [2 years]
Collect blood samples and analyze for T cell subgroup by flow cytometry at specified intervals before and after treatment with HRYZ-T101.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

1. The patient must be willing to sign the informed consent form.
1. Age ≥18 years and ≤75 years.
1. Metastatic or recurrent solid tumors with confirmed HPV18 infection based on TNM & FIGO staged histopathological investigation. .
1. Subjects who have failed anti-tumor treatment in the past and lack effective treatment options.
1. HPV18 positive and HLA-DRB1*0901 allele.
1. ECOG performance status ≤1.
1. Estimated life expectancy ≥ 3 months.
1. Patients must have at least one measurable lesion defined by RECIST 1.1.
1. Patients with any organ dysfunction as defined below:

Leukocytes≥3.0 x 10^9/L;
blood platelets ≥75 x 10^9/L;
hemoglobin≥85g/L;
Absolute lymphocyte count≥0.8 x 10^9/L
Serum albumin ≥ 30g/L;
total bilirubin≤1.5×ULN; ALT/AST≤3×ULN or ≤5×ULN for liver metastases;
Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN;
INR≤1.5×ULN; APTT≤1.5×ULN;
LVEF≥50%;
SpO2≥92%.

1. Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 1 year after receiving HRYZ-T101 cell transfusion treatment. HCG test for female with potential fertility must be negative within 7 days before apheresis.

Exclusion Criteria:

1. Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
1. Those who have undergone systemic anti-tumor treatment within 4 weeks before apheresis, including who have received conventional chemotherapy, large-area radiotherapy, targeted therapy, immunotherapy or biological therapy, and other anti-tumor treatment. Have received small molecule targeted drugs and oral fluorouracils or Chinese herbal medicine within 2 weeks before apheresis.
1. Have received any investigational drug within 4 weeks before apheresis, or have participated in another clinical study at the same time.
1. Have received any cell therapy products before.
1. Those who have undergone major surgery within 4 weeks before apheresis, or minor surgery within 2 weeks before apheresis.
1. Toxicity of previous treatment has not been mitigated or ≤ Grade 1 before apheresis.
1. Have received live attenuated vaccine or adenovirus vector vaccine within 4 weeks before apheresis.
1. Have central nervous system metastasis with symptoms.
1. Subjects with clinical cardiac symptoms or diseases that cannot be well controlled.
1. Subjects with serious or uncontrolled systemic disease or any unstable systemic disease.
1. Subjects with active infection requiring systemic treatment with anti-infective drugs within 2 weeks before apheresis.
1. Subjects have any active autoimmune disease or history of autoimmune disease.
1. Have received immunosuppressive agents, or systemic corticosteroids, immunomodulators within 2 weeks before apheresis.
1. Subjects with other malignant tumors. Except for: (1) Carcinoma in situ with curative treatment and no evidence of recurrence for at least 2 years; (2) the primary malignant tumor has been completely resected and achieved CR for ≥ 2 years.
1. Subjects with history of thromboembolism ≥ Grade 3 within 6 months before apheresis, or is receiving thrombolytic or anticoagulant for high-risk of thromboembolism.
1. Known HIV or syphilis infection, and/or active hepatitis B virus or hepatitis C virus infection.
1. Organ transplanters and allogeneic cell transplanters.
1. Subjects with active pulmonary tuberculosis infection within 1 year or have not received treatment at least 1 year before apheresis.
1. Pregnant or lactating female, or those whose HCG test is positive before enrollment.
1. According to the judgment of the researcher, those who are not suitable for the group, such as poor compliance.